Objective: Impaired renal function is associated with higher risk of upper gastrointestinal bleeding (UGIB) in patients with chronic kidney disease and not on dialysis (CKD-ND). It is unclear if UGIB increases risk of chronic dialysis. The aim of the study was to investigate risk of chronic dialysis in CKD-ND patients with UGIB.
INTRODUCTION
Upper gastrointestinal bleeding (UGIB) is a common gastrointestinal disorder in patients with chronic kidney disease and not receiving dialysis (CKD-ND). 1 2 In patients with CKD-ND, the risk of UGIB is negatively associated with their renal function. 1 UGIB not only increases the risk of hospitalisation but also increases in-hospital mortality in patients with CKD-ND and CKD 5 patients on dialysis. 3 The increased all-cause mortality associated with UGIB is usually explained by the worsened comorbid conditions caused by the UGIB. [3] [4] [5] Dialysis may be needed in patients with CKD-ND when UGIB leads to decreased intravascular volume and subsequent prerenal acute kidney injury. 6 Furthermore, incidence of UGIB episodes may be the deciding factor for progression of CKD and may lead to chronic dialysis if patients with CKD-ND do not recover from the acute kidney injury. However, the long-term effect of UGIB on the risk of chronic dialysis in patients with CKD-ND is not clear. The aim of the study was to investigate the risk of chronic dialysis after UGIB in patients with CKD-ND. increases all-cause mortality but also increases the risk of chronic dialysis in patients with chronic kidney disease (CKD). ▪ This association is shown in a cohort of patients with CKD with adjustments for confounders. ▪ The generalisability of this finding may be limited by the study being conducted in one hospital and on a single ethnic group.
MATERIALS AND METHODS
patients with CKD-ND stages 3-5 diagnosed by nephrologists and no exclusion criteria were applied. The CKD programme, supported by National Health Insurance Taiwan, includes clinical endocrinologists, nephrologists, CKD nurses, dieticians and social workers. The purpose of the CKD programme is to monitor the progression of patients with CKD. Laboratory measurements and CKD education are performed at least four times a year. The UGIB was identified from review of medical records and the date of UGIB was recorded. All patients were followed to the date of initiation of chronic dialysis including haemodialysis and peritoneal dialysis, loss to follow-up, death or until September 2012. Two patients, who received kidney transplants, were excluded in the analysis because the timing of kidney transplantation was not related to uraemic symptoms. As we aimed to investigate risk of chronic dialysis, patients who received dialysis for less than 3 months and patients who discontinued dialysis because of a recovery of renal function were excluded.
Definition and measurements UGIB was defined as melena, haematemesis, or the presence of red blood in gastric lavage fluid, together with observation of a bleeding lesion or a lesion likely to have bled on endoscopy of the upper digestive tract. Coronary artery disease (CAD) was defined as a positive exercise test, angiographic findings of at least one stenosis of more than 50% or positive findings on scintigraphy. 7 Diabetes mellitus was defined as use of insulin, use of oral antidiabetic medication or a fasting plasma glucose level of 126 mg/dL or more. 8 Hypertension was defined as taking antihypertensives without regard to the actual measurement of blood pressure, or having a systolic blood pressure reading greater than 140 mm Hg or a diastolic blood pressure reading greater than 90 mm Hg. 9 Patients' primary kidney disease, including diabetes nephropathy, chronic glomerulonephritis (CGN) and hypertensive nephropathy, was diagnosed by the primary care physician and recorded at enrolment. Each patient's body mass index (BMI), blood urea nitrogen (BUN) and creatinine were measured at enrolment. Serum calcium, phosphorus, albumin, urine albumin/creatinine ratio (ACR) and urine protein/creatinine ratio (PCR) were measured 3 months after enrolment. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Collaboration formula. 10 The formula for white or other race was used because the patients were all Chinese. The time-varying analysis used an average of three eGFR measurements. Medications associated with a higher risk of UGIB, including steroids, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, clopidogrel and warfarin, were recorded based on the review of medical records.
Outcomes measurements
The CKD nurses recorded the outcomes (dialysis for more than 3 months or mortality) and date of the outcomes in the computerised case-management system. The CKD nurses also checked patients' status in the computerised medical record system in CMUH and contacted patients who did not return to the outpatient every 6 months. The percentage of patients who were lost to follow-up was 6% in the CKD programme. The outcomes were validated by a study nurse through a review of medical records and the study nurse was blinded to the aim of the study, and physicians performed the analysis.
Statistical analysis
Data were reported as mean±SD, median (IQR), or frequency ( percentage), as appropriate. All continuous variables were tested using skewedness and kurtosis test for their normality. Data were analysed using Student's t test for parametric variables, Kolmogorov-Smirnov test for non-parametric variables, or χ 2 test for categorical variables. Factors with a p value <0.05 in univariable Cox proportional hazard regression and risk factors of chronic dialysis in the literature were considered as possible confounders. Possible confounders for all-cause mortality and chronic dialysis were analysed using multivariable Cox proportional hazard regression. An adjusted HR (aHR) and 95% CIs of aHR in multivariable Cox regression with adjustments for age, gender and eGFR were calculated. We utilised competing-risks analysis 11 with adjustments for confounders identified in Cox regression because the risk of chronic dialysis may be overestimated if patients' death was not taken into consideration. 12 13 An adjusted subdistribution HR (aSHR) and 95% CI of aSHR were calculated in competing-risks analysis with adjustments for age, gender, eGFR and confounders for chronic dialysis. The primary outcome was defined as chronic dialysis and the competing event was patient's death in the competing-risks analysis. All analyses were performed using Stata V.13 SE (StataCorp, Texas, USA) and a p value <0.05 was considered statistically significant.
Ethical considerations
Internal review board approval (DMR 99-IRB-301) was obtained for the review of medical records, and the need for informed consent was waived.
RESULTS

Patient characteristics
We identified 3126 patients with CKD-ND stages 3-5 including 1691 males and 1435 females, aged 65 ±14 years (table 1) . Diabetes nephropathy and chronic glomerulonephritis (CGN) were the major forms of primary kidney disease. The basal eGFR of the patients was 21 (11-37) mL/min/1.73 m 2 and the urine PCR was 1.4 (0.5-3.6) g/g at enrolment. Patients with UGIB were older and more often had diabetes, a lower eGFR, lower haemoglobin, higher BUN, higher creatinine and lower serum albumin. They, however, had similar use of steroid, NSAIDs, aspirin, clopidogrel and warfarin. There were no differences in serum calcium and phosphate levels of the patients with UGIB and the patients without. The times of follow-up were similar in the patients with UGIB and the patients without ( p=0.38, table 2). The proportion of the patients with UGIB who started chronic dialysis was higher than that of the patients without UGIB (61.5% vs 27.4%, p<0.01). Patients with UGIB were associated with a higher allcause mortality than patients without UGIB (11.6% vs 5.6%, p<0.01).
UGIB and risk of mortality UGIB was independently associated with higher all-cause mortality (table 3) with an aHR of 1.51 (95% CI 1.07 to 2.13, p=0.02). Patients' age, eGFR and serum albumin were independently associated with all-cause mortality.
The aHR was 1.05 for every one additional year (95% CI 1.04 to 1.07, p<0.01), 0.99 for every mL/min/1.73 m 2 of eGFR (95% CI 0.0.98 to 1.00, p<0.01) and 0.52 per g/ dL of serum albumin (95% CI 0.42 to 0.65, p<0.01). Diabetes, CAD, haemoglobin and PCR were not associated with all-cause mortality. Use of steroid, NSAIDs, clopidogrel and warfarin was not associated all-cause mortality, either.
UGIB and risk of chronic dialysis UGIB was associated with an increased risk of chronic dialysis with an aHR of 1.29 (95% CI 1.11 to 1.50, p<0.01). Diabetes was independently associated with increased risk of chronic dialysis with an HR of 1.49 (95% CI 1.30 to 1.72, p<0.01). Haemoglobin and serum albumin were associated with lower risk of chronic dialysis. PCR was associated with increased risk of chronic figure 1 .
DISCUSSION
In this cohort of patients with CKD-ND stages 3-5, UGIB was associated with higher risk of chronic dialysis. The association of UGIB and risk of chronic dialysis was further validated using competing-risks analysis. The competing-risks analysis was critical to this study because UGIB was associated with increased all-cause mortality. UGIB can be a complication of uraemia because of the uraemic coagulopathy. In this study, patients with UGIB started chronic dialysis after a median of 1.2 (IQR: 0.7-1.3) years. Uraemic coagulopathy associated UGIB therefore may not be one of the uraemic symptoms that required dialysis in these patients. In summary of our previous studies 1 14 15 and this study (figure 2), patients with CKD-ND were more at risk for developing UGIB, and UGIB may further accelerate the progression of CKD to chronic dialysis. The common aggravating factors of CKD and UGIB are anaemia, 16 diabetes and hypoalbuminaemia. 1 In addition, higher GFR and uses of ACE inhibitor (ACEi) or angiotensin II receptor blocker (ARB) may protect UGIB in this scenario. 15 Some beneficial effects of ACEi and ARB may come from their association with decreased risk of UGIB. 15 Most patients with CKD died from CAD during the course of CKD progression and only some of the patients with CKD started chronic dialysis. [17] [18] [19] In our study, the proportion of patients who started chronic dialysis was higher than that of patients who died. This was not only observed in our previous studies 1 20 but also in other cohorts of patients with CKD in Taiwan. 21 The high prevalence of chronic dialysis in Taiwan may be explained by an ethnic difference 22 or the effectiveness of multidisciplinary care for CKD in Taiwan. Figure 1 Cumulative incidence of chronic dialysis in patients with and without upper gastrointestinal bleeding (UGIB), using competing-risks regression with adjustments for age, gender, renal function, diabetes, haemoglobin, albumin and urine protein/creatinine ratio. The primary event was chronic dialysis and the competing event was all-cause mortality. Diabetes was associated with the risk of chronic dialysis because diabetes is a well-known confounder of dialysis. NSAIDs were also well-known risk factors for UGIB and chronic dialysis, 23 but we did not find any significant association of NSAIDs and chronic dialysis. Aspirin, clopidogrel and warfarin were not associated with the risk of chronic dialysis in patients with CAD, either. Steroids treatment was relatively common in patients with CKD 24 but only 3% of patients took steroids in this study. Steroids treatment was not associated with the risk of chronic dialysis in this study. The limited number of patients who took these medications in this study may explain this result. In addition, nausea and vomiting can be uraemic symptoms 25 and are indications of dialysis. Nausea and vomiting are common in patients with UGIB. 26 Although some patients with CKD initiated dialysis because of UGIB-related nausea and vomiting rather than uraemic symptoms, the percentages of patients with nausea and vomiting at the initiation of dialysis were similar among patients with UGIB and in those without. In addition, we excluded patients who underwent dialysis for less than 3 months and those who discontinued dialysis because of a recovery of renal function. UGIB-related nausea/vomiting did not explain the association of UGIB and chronic dialysis in this study.
The limitations of this study were its observational study design and the inclusion of all patients in a single hospital in Taiwan. This may limit the generalisability of our finding to other ethnic groups. More studies of various ethnic groups and multiple institutions are required to confirm our results. Patients of a CKD programme were analysed in this study and therefore patient selection bias cannot be avoided. We also recorded proton-pump inhibitor treatment for UGIB but did not find any beneficial effect of this treatment in decreasing risk of chronic dialysis and all-cause mortality. In spite of its limitations, this is the first study to show an association of UGIB and chronic dialysis, independent of all confounders of chronic dialysis. This suggests that UGIB not only leads to acute kidney injury but also results in long-term consequence of irreversible kidney injury in this population.
CONCLUSIONS UGIB is associated with increased risk of chronic dialysis in patients with CKD stages 3-5 and not receiving dialysis. This association is independent of age, gender, basal renal function, diabetes, haemoglobin, albumin and urine protein levels. More studies will be warranted to investigate if prevention of UGIB may slow the progression of CKD and delay the need of dialysis in patients with CND-ND.
